Dr. Reddy’s Laboratories has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of CYMBALTA® (Duloxetine¬ Delayed-Release Capsules) in the US market on June 26, 2014. Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA).
The CYMBALTA® brand and generic had U.S. sales of approximately $5.04 Billion MAT for the most recent twelve months ending in April 2014 according to IMS Health*.
Dr. Reddy’s Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts. Duloxetine is not approved for use in pediatric patients.
The CYMBALTA® brand and generic had U.S. sales of approximately $5.04 Billion MAT for the most recent twelve months ending in April 2014 according to IMS Health*.
Dr. Reddy’s Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts. Duloxetine is not approved for use in pediatric patients.
